Investegate announcements from QuantuMDx Group Ltd, QuantuMDx announces approval of its Rapid Q-POCTM SARS-CoV-2 assay in the UK under CTDA legislation
QuantuMDx announces approval of its Rapid Q-POCTM SARS-CoV-2 assay in the UK under CTDA legislation NEWCASTLE UPON TYNE, UK, 22 February 2022. QuantuMDx Group Limited ("QuantuMDx"), today announces
RNS Number: 1141 Q Novacyt S.A. 24 February 2021 Novacyt S.A.. Paris, France and Camberley, UK- 24 February 2021- Novacyt, an international specialist.
This is a correction to the Research and Development Update announcement published at 7:00am on 24 February 2021 (RNS number 1141Q) which has been amended with the following underlined additions to make it consistent with the French announcement released on Euronext at 8:00am CET on 24 February 2021. Under the subtitle Launch of CE Mark COVID-HT Direct · Novacyt announces the launch of its next generation high-throughput PCR test for COVID-19 (COVID-HT Direct), which has been CE Mark approved using independent validated data. · The new COVID-HT Direct uses pharyngeal swabs collected in viral transport media (without guanidine) and saline Under the subtitle Successful completion and publication of TVG validation of PROmate™